Celiac Diseases Drugs Market Analysis North America, Europe, EMEA, APAC : US, Canada, China, Germany, UK - Size and Forecast 2023-2027

Published: Sep 2023

Pages: 155

SKU: IRTNTR45214

Snapshot

Celiac Diseases Drugs Market 2023-2027

The global celiac diseases drugs market size is estimated to grow by USD 701.59 million at a CAGR of 17.01% between 2022 and 2027.

Several government initiatives are driving the market by funding the research, improving awareness among the people, and by providing therapeutics at subsidized prices. Globally, government organizations and non-profit organizations are taking numerous initiatives to increase awareness of rare diseases, such as celiac disease. For instance, Celiac Diseases Foundation creates awareness regarding celiac diseases through May Celiac Disease Awareness Month to educate, advocate, and accelerate research for celiac disease. In addition, hospitals also take initiatives to create awareness regarding celiac diseases. For instance, Stanford Children's Health creates awareness through "Celebrating Celiac Disease Awareness Month" in May Month. Several other organizations, such as the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the University of Oxford and Health Economics Research Centre are taking initiatives to create awareness regarding celiac diseases. Therefore, such government initiatives will drive the growth of the global celiac diseases market during the forecast period.

Technavio has segmented the market into therapy, route of administration, and geography

The therapy segment is classified into first line treatment and second-line treatment
The route of administration segment is classified into oral and parenteral
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Celiac Diseases Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

Celiac Diseases Drugs Market Segmentation by Therapy, Route Of Administration and Geography Analysis

Therapy Analysis

First line treatment

The market share growth by the first line treatment segment will be significant during the forecast period. For celiac disease, the first line of treatment includes treatments that are mainly associated with the prevention and cure of the disease. This segment included a gluten-free diet, which is now an available choice for the prevention of triggering immune responses leading to different clinical manifestations.

Get a glance at the market contribution of various segments View a PDF Sample

The first line segment was the largest and was valued at USD 307.17 million in 2017. The first line of treatment is presently dominated by a gluten-free diet as this is the only available option for the prevention of immune response. Furthermore, the current volume-driven market is expected to change into a value-driven market upon the successful launch of a few novel late-stage pipeline molecules. However, due to economic constraints, these new launches will find it challenging to penetrate the low economic regions, which could restrict market growth. Therefore, the segment is anticipated to experience significant growth, thereby fueling the growth of the market during the forecast period.

Route Of Administration Analysis

Oral

Oral routes of administration are becoming increasingly popular in the global celiac disease drug market due to their simplicity and patient compliance. Oral medicines have gained huge acceptance as an effective approach to controlling celiac disease, addressing symptoms, and lowering inflammation in the digestive tract. Further, in severe situations, oral immunosuppressants such as azathioprine (Imuran) may be administered to control the immunological response. Such a trend is expected to continue as pharmaceutical companies spend on R&D to generate more new oral medicines that enhance the quality of life for celiac disease patients. This, in turn, will drive the growth of the market during the forecast period.

Parenteral

Parenteral administration has seen steady expansion in the global celiac disease drugs market due to the limited effectiveness of oral therapies for this autoimmune disease. Celiac disease, which is characterized by gluten intolerance, necessitates precision medicine delivery to treat symptoms and prevent complications. Further, to suppress inflammation during the acute phases of the condition, corticosteroids such as prednisone can be injected intravenously or intramuscularly. The increased awareness of celiac disease and the development of novel parenteral therapeutics are expected to fuel additional growth in this market segment. Due to this growth trend, the market is expected to witness growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 58% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In 2022, North America held the highest share of the global celiac disease drugs market. The market is expected to grow due to factors such as the rising prevalence of celiac diseases, growing awareness of celiac diseases, the presence of key companies, and a strong pipeline of drugs in the region. Due to the increase in the consumption of gluten-containing food, the prevalence of the disease is growing in the US. The consumption of beer and fast food is increasing in the region, which is a major risk factor for celiac disease.

For instance, around 63% of American adults drink alcohol, and their favored beverage is beer. Around 42% of American drinkers prefer beer and its high consumption is a major risk factor for celiac disease. Also, fast-food consumption is growing in the region due to busy work life and a growing preference for ready-to-eat food. Therefore, the high consumption of gluten-containing food and the growing prevalence of celiac diseases are anticipated to drive the growth of the regional market during the forecast period.

COVID Recovery Analysis

In 2020, the outbreak of the COVID-19 pandemic altered the celiac disease drugs market in North America. Further, the introduction of COVID-19 vaccinations in 2021 provides a more stable environment for the celiac disease drug market in North America. Patients sought prompt diagnosis and treatment as their trust in healthcare systems recovered, favorably boosting drug sales. Further, the celiac disease drug market in North America is expected to grow steadily. Therefore, advances in diagnostic tools and treatments, such as gluten-targeted therapy, are anticipated to drive the growth of the regional market during the forecast period.

Buy Now Full Report and Discover More

Key Celiac Diseases Drugs Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Adaptive Biotechnologies Corp. - The company offers celiac disease drugs such as Immunoseq dx, Pairseq and Trutcr.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Celiac Diseases Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Celiac Diseases Drugs Market Drivers

Higher consumption of gluten-containing food is notably driving the market growth. Due to the high consumption of food containing gluten, celiac disease is characterized by an increase in gluten deposition in the body. Pizza, cake, soups, beer, bread, cookies, pasta, and burgers are some of the widely consumed foods that contain gluten. Globally, the consumption of fast food such as pizza and burgers is increasing. For instance, in the US, the consumption of pizza is at a moderate level.

Moreover, the rise in per capita income, changing lifestyle, addiction toward junk food and beverages, and the introduction of ready-to-use packaged eateries have contributed to the upsurge in the consumption of gluten-containing food. Thus, The chances of acquiring celiac disease are also high due to the high consumption of gluten-containing food. These factors are anticipated to fuel the growth of the market during the forecast period.

Significant Celiac Diseases Drugs Market Trends

Increasing promising developments in celiac treatment is an emerging trend shaping the market growth. Nowadays, for celiac disease management, there is no approved drug indicated. However, the current pipeline is robust. Such drugs are anticipated to be approved and launched during the forecast period. With higher impacts, these drugs will change market dynamics.

Moreover, these drugs act by various mechanisms (s) and with various approaches to treating celiac diseases at multiple targets. These drugs will drive the market and change the current market dynamics during the forecast period.

Major Celiac Diseases Drugs Market Challenges

The complexity of the disease is a significant challenge hindering market growth. Celiac disease is associated with a variety of symptoms and these symptoms are associated with various organs throughout the body. These symptoms make the disease more intricate and, therefore, difficult to manage. Similarly, celiac disease is a multisystem disorder that impacts various human organs.

Moreover, they may face immune-mediated disorders while consuming gluten in cases where celiac disease is hereditary, and celiac disease drugs may not be effective in such cases. Therefore, such factors may adversely influence the growth of the market during the forecast period.

Buy Now Full Report and Discover More

Key Celiac Diseases Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Celiac Diseases Drugs Market Customer Landscape

Segment Overview

The celiac diseases drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Therapy Outlook (USD Million, 2017 - 2027)
- First line treatment
- Second-line treatment

Route Of Administration Outlook (USD Million, 2017 - 2027)
- Oral
- Parenteral

Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- ROW
  - Brazil
  - Argentina
  - Australia

Celiac Diseases Drugs Market Scope
Report Coverage	Details
Page number	155
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 17.01%
Market growth 2023-2027	USD 701.59 million
Market structure	Fragmented
YoY growth 2022-2023(%)	15.85
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 58%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ImmunogenX Inc., Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, and Zedira GmbH
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Celiac Diseases Drugs Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the celiac diseases drugs market between 2023 and 2027
Precise estimation of the celiac disease drugs market size and its contribution of the market in focus to the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of celiac diseases drugs market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global celiac diseases drugs market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global celiac diseases drugs market 2017 - 2021 ($ million)

4.2 Therapy Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)

4.3 Route of Administration Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

6.1 Market segments
- Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)

6.2 Comparison by Therapy
- Exhibit 32: Chart on Comparison by Therapy
- Exhibit 33: Data Table on Comparison by Therapy

6.3 First line treatment - Market size and forecast 2022-2027
- Exhibit 34: Chart on First line treatment - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on First line treatment - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on First line treatment - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on First line treatment - Year-over-year growth 2022-2027 (%)

6.4 Second-line treatment - Market size and forecast 2022-2027
- Exhibit 38: Chart on Second-line treatment - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Second-line treatment - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Second-line treatment - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Second-line treatment - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Therapy
- Exhibit 42: Market opportunity by Therapy ($ million)
- Exhibit 43: Data Table on Market opportunity by Therapy ($ million)

7 Market Segmentation by Route of Administration

7.1 Market segments
- Exhibit 44: Chart on Route of Administration - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Route of Administration - Market share 2022-2027 (%)

7.2 Comparison by Route of Administration
- Exhibit 46: Chart on Comparison by Route of Administration
- Exhibit 47: Data Table on Comparison by Route of Administration

7.3 Oral - Market size and forecast 2022-2027
- Exhibit 48: Chart on Oral - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Oral - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Oral - Year-over-year growth 2022-2027 (%)

7.4 Parenteral - Market size and forecast 2022-2027
- Exhibit 52: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)

7.5 Market opportunity by Route of Administration
- Exhibit 56: Market opportunity by Route of Administration ($ million)
- Exhibit 57: Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 59: Chart on Market share by geography 2022-2027 (%)
- Exhibit 60: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 61: Chart on Geographic comparison
- Exhibit 62: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Canada - Market size and forecast 2022-2027
- Exhibit 83: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.9 Germany - Market size and forecast 2022-2027
- Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.10 UK - Market size and forecast 2022-2027
- Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.11 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 99: Market opportunity by geography ($ million)
- Exhibit 100: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 101: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 102: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 103: Overview on factors of disruption

11.4 Industry risks
- Exhibit 104: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 105: Vendors covered

12.2 Market positioning of vendors
- Exhibit 106: Matrix on vendor position and classification

12.3 Adaptive Biotechnologies Corp.
- Exhibit 107: Adaptive Biotechnologies Corp. - Overview
- Exhibit 108: Adaptive Biotechnologies Corp. - Product / Service
- Exhibit 109: Adaptive Biotechnologies Corp. - Key offerings

12.4 Almirall SA
- Exhibit 110: Almirall SA - Overview
- Exhibit 111: Almirall SA - Product / Service
- Exhibit 112: Almirall SA - Key news
- Exhibit 113: Almirall SA - Key offerings

12.5 Amgen Inc.
- Exhibit 114: Amgen Inc. - Overview
- Exhibit 115: Amgen Inc. - Product / Service
- Exhibit 116: Amgen Inc. - Key offerings

12.6 AMYRA Biotech AG
- Exhibit 117: AMYRA Biotech AG - Overview
- Exhibit 118: AMYRA Biotech AG - Product / Service
- Exhibit 119: AMYRA Biotech AG - Key offerings

12.7 BioLineRx Ltd.
- Exhibit 120: BioLineRx Ltd. - Overview
- Exhibit 121: BioLineRx Ltd. - Product / Service
- Exhibit 122: BioLineRx Ltd. - Key offerings

12.8 Bristol Myers Squibb Co.
- Exhibit 123: Bristol Myers Squibb Co. - Overview
- Exhibit 124: Bristol Myers Squibb Co. - Product / Service
- Exhibit 125: Bristol Myers Squibb Co. - Key news
- Exhibit 126: Bristol Myers Squibb Co. - Key offerings

12.9 Calypso Biotech BV
- Exhibit 127: Calypso Biotech BV - Overview
- Exhibit 128: Calypso Biotech BV - Product / Service
- Exhibit 129: Calypso Biotech BV - Key offerings

12.10 GlaxoSmithKline Plc
- Exhibit 130: GlaxoSmithKline Plc - Overview
- Exhibit 131: GlaxoSmithKline Plc - Business segments
- Exhibit 132: GlaxoSmithKline Plc - Key news
- Exhibit 133: GlaxoSmithKline Plc - Key offerings
- Exhibit 134: GlaxoSmithKline Plc - Segment focus

12.11 Glenmark Pharmaceuticals Ltd.
- Exhibit 135: Glenmark Pharmaceuticals Ltd. - Overview
- Exhibit 136: Glenmark Pharmaceuticals Ltd. - Product / Service
- Exhibit 137: Glenmark Pharmaceuticals Ltd. - Key offerings

12.12 ImmunogenX Inc.
- Exhibit 138: ImmunogenX Inc. - Overview
- Exhibit 139: ImmunogenX Inc. - Product / Service
- Exhibit 140: ImmunogenX Inc. - Key offerings

12.13 Johnson and Johnson
- Exhibit 141: Johnson and Johnson - Overview
- Exhibit 142: Johnson and Johnson - Business segments
- Exhibit 143: Johnson and Johnson - Key news
- Exhibit 144: Johnson and Johnson - Key offerings
- Exhibit 145: Johnson and Johnson - Segment focus

12.14 Precigen Inc.
- Exhibit 146: Precigen Inc. - Overview
- Exhibit 147: Precigen Inc. - Business segments
- Exhibit 148: Precigen Inc. - Key offerings
- Exhibit 149: Precigen Inc. - Segment focus

12.15 Sanofi
- Exhibit 150: Sanofi - Overview
- Exhibit 151: Sanofi - Business segments
- Exhibit 152: Sanofi - Key news
- Exhibit 153: Sanofi - Key offerings
- Exhibit 154: Sanofi - Segment focus

12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 155: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 156: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Key offerings

12.17 Teva Pharmaceutical Industries Ltd.
- Exhibit 159: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 160: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 163: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 164: Inclusions checklist
- Exhibit 165: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 166: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 167: Research methodology
- Exhibit 168: Validation techniques employed for market sizing
- Exhibit 169: Information sources

13.5 List of abbreviations
- Exhibit 170: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

celiac diseases drugs market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis